

Casirivimab & Imdevimab (Regen-Cov) Order Form for Treatment of COVID (+) patients

Patient Name	DOB					
Address						
Phone #						
**Symptom Onset Date:	Symptoms:					
Date patient tested positive:	**Please fax copy of test result with order if available					
Patient must meet ALL of the follow	ing criteria:					
□ Positive test for SARS-CoV-2						
Onset of symptoms within the pase	st 7 days					
Patient is 18 years of age or older						
Not requiring supplemental oxyge	n					
No increase in baseline oxygen requirements for patients on baseline O2 from a non-COVID-19						
comorbidity						
No prior administration of Regen-	COV or bamlanivimab/etesevimab within the last 6 months					
AND						
One (1) of the following risk factors:						
\Box Age \geq 50						
□ BMI ≥ 30						
Pregnancy						
Immunosuppressed						
 Solid organ transplant, advanced HIV, active chemotherapy, ESLD 						
Use of biologic agents for treatment of underlying disease: TNF alpha inhibitor for RA or						
Crohn's, chronic hi	gh dose steroids					
Chronic Kidney Disease (stage 4 and above, ESRD)						
Diabetes Mellitus (on insulin therapy or oral hypoglycemics)						
Chronic Lung Disease: COPD, Asthma, Interstitial Lung Disease, Cystic Fibrosis, or Pulmonary Fibrosis						
Cardiovascular Disease: Hypertension, Coronary Artery Disease or Congestive Heart Failure Neurodevelopmental disorders (Ex. Cerebral palsy)						
·	Medical-related technological dependence (Ex. Tracheostomy, gastrostomy, etc.)					
□ Sickle Cell disease						
Patients who meet the above criteria will b treatment.	be eligible to receive Casirivimab & Imdevimab (Regen-Cov)					



Casirivimab & Imdevimab (Regen-Cov) Order Form for Treatment of COVID (+) patients

Rx:					
IV Casirivimab 600mg & I	mdevima	ab 600mg (Regen-Cov) adde	d to 100 mL of 0.9	% sodium chloride for total	
 volume of 110 mL x 1 dose Infuse over 21 minutes Administer using a 0.2-micron filter Observe patient for at least 1 hour following administration 				KHN infusion reaction protocol will be utilized if a patient has an infusion-related or hypersensitivity reaction.	
 Start primary line wi infusion is complete 		0.9% sodium chloride and give	the remainder of the	bag as a bolus after the Regen-Cov	
Pre-meds (optional):				Consider premeds for patients	
🗆 Tylenol 650 mg po	or	🗆 Tylenol 1000 mg po		with allergic tendencies or who have had allergic reactions to	
🗆 Benadryl 25 mg po	or	🗆 Benadryl 25 mg IV		an immunoglobulin product.	
Methylprednisolone 40) mg IV				
□ Other:					
Prescriber			Date		
Prescriber Signature					
Address:			Phone	Fax:	